Should flow-volume loop be monitored in sleep XXXX @entity1 treated with continuous positive airway pressure?

@entity1 @entity748 @entity387 @entity2488 @entity565 @entity73 @entity27 @entity1030 @entity386
Nasal continuous positive airway pressure (nCPAP) has been widely established in the treatment of @entity27 ( @entity27 ). However, only few studies have evaluated long-term effects of this treatment on lung function. This study assesses the effect of nCPAP on lung function parameters and response to bronchodilators in 50 @entity27 @entity1 . Spirometry and arterial blood gas measurements were performed before starting nCPAP and after 16.8 +/- 8 months of treatment. Of the 50 study @entity1 (55 +/- 12 years, with an @entity386 / @entity387 index of 47 +/- 34h(-1)), 15 had @entity565 , 13 had @entity1030 ( @entity1030 ) and 22 had no obstructive @entity1030 (NOAD). In the entire population, significant decreases in FEF50 (from 69 +/- 38% to 61 +/- 30%, P < 0.005), FEF25 (from 53 +/- 34% to 46 +/- 28%, P < 0.05) and FEF25-75 (from 65 +/- 33% to 57 +/- 27%, P < 0.005) were observed after treatment. No @entity73 was found in @entity1030 and @entity748 @entity1 . In contrast, lung function was changed in the NOAD group where FEF50, FEF25 and FEF25-75 as well as FEV1 and FEV1/VC ratio were significantly reduced. Moreover, @entity2488 occurred in five of 22 @entity1 of this group. These results suggest that tolerance of nCPAP should be handled by long-term follow-up of flow-volume loops.
